PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BTG Joins Global Liver Institute Partnership Network to Transform Care for Liver Cancer Patients - BTG, a global leader in interventional oncology, announced that it has joined the Global Liver Institute’s Partnership Network as a founding member - GlobalLiver.org / BTG-IM.com
BTG Joins Global Liver Institute Partnership Network to Transform Care for Liver Cancer Patients

 

NewswireToday - /newswire/ - Farnham, Surrey, United Kingdom, 2016/06/09 - BTG, a global leader in interventional oncology, announced that it has joined the Global Liver Institute’s Partnership Network as a founding member - GlobalLiver.org / BTG-IM.com. LSE: BTG

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The Global Liver Institute (GLI) is the innovation and collaboration platform for the liver community worldwide. BTG will provide expertise and support on key initiatives to help transform care for liver cancer patients.

GLI’s portfolio of liver cancer initiatives includes the Reimagine Liver Cancer stakeholder workshop, the HCC360 Registry & Biorepository, and the Personalized Medicine in Liver Diseases meeting.

GLI established the Partnership Network in January 2016 to bring together like-minded organizations and individuals to fundamentally transform advocacy in the liver field. The Partnership Network addresses the need for initiatives that cross disciplines, sectors, and stakeholder groups to advance patient-centered research, education, and health system delivery solutions.

“We are delighted to welcome BTG to our Partnership Network. Their knowledge and experience in the complexities of liver cancer care will be an important contribution to the Partnership Network” stated Donna R. Cryer, JD, President, & CEO of the Global Liver Institute. “According to the most recent data, liver cancer is the second most deadly cancer worldwide and one of the few cancers that is rising in incidence.”

BTG’s interventional oncology portfolio is transforming the way cancer is being treated by discovering and developing differentiated therapeutic innovations for hard to treat primary and secondary liver cancers. The BTG interventional oncology portfolio offers the flexibility to treat patients through embolization and internal radiation, with minimally invasive treatments that go precisely where they are needed. BTG is also conducting research in these areas to extend the reach of science and technology over liver disease.

Ken Pugh, BTG Vice President, Commercial Development and Interventional Oncology Marketing, the Americas remarked,“We are excited to come on board as a founding member of the Global Liver Institute Partnership Network. BTG is committed to improving patient outcomes by delivering continued advancements in personalized, loco-regional cancer therapies. We believe passionately that interventional oncology has the power to improve human health and our partnership with the GLI will help to build connections across the liver community to transform cancer care.”

GLI and BTG call for more public attention to liver cancer, mechanisms that promote earlier diagnosis, increased transparency and education on the dangers of cumulative risk factors for liver cancer, assistance for patients and families navigating the liver cancer care journey, and the need for increased participation in research.

The GLI board includes renowned liver cancer experts Lewis R Roberts, MB, ChB, PhD of Mayo Clinic and Melanie Thomas, MS, MS at the Gibbs Cancer Center & Research Institute, the founder of CanLiv, the Hepatobiliary Cancers Foundation now part of GLI.

About The Global Liver Institute
The Global Liver Institute (globalliver.org) is a 501©(3) tax exempt not-for-profit organization, headquartered in Washington, D.C., United States. Our Vision is for liver health to take its place on the global public health agenda commensurate with its prevalence and impact. Our Mission is to improve the impact of the liver community by promoting innovation, collaboration, and scaling optimal approaches to eradicating liver diseases.

About BTG Interventional Medicine
BTG Interventional Medicine (btg-im.com) is part of BTG plc, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavors to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots, and varicose veins.

GLI Contact: Donna Cryer, President & CEO
P: +1 202-603-3493 - E: dcryer[.]globalliver.org.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BTG Joins Global Liver Institute Partnership Network to Transform Care for Liver Cancer Patients

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

BTG Interventional Med. | Global Liver Institute
Publisher Contact: Chris Sampson - BTGplc.com 
+44(0)20 7575 1595 / +44(0)7773 251178 (mobile) chris.sampson[.]btgplc.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Biocompatibles UK Ltd / BTG Plc / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)